Morphological verification of renal lesion as a compulsory stage in the diagnosis of Fabry disease

Cite item

Full Text


The paper describes a case of Fabry disease in a patient in whom kidney biopsy enabled the renal lesion be characterized in detail. Fabry nephropathy-associated kidney tissue changes, including renal lesion, have been verified using electron microscopy of renal tissue.

Full Text

Морфологическая верификация почечного поражения как обязательный этап диагностики болезни Фабри. - Аннотация. Представлено наблюдение пациента с болезнью Фабри (БФ), у которого почечное поражение было детально охарактеризовано с помощью биопсии почки. Типичные для нефропатии, ассоциированной с БФ, изменения почечной ткани, в том числе поражение почек, были подтверждены при электронной микроскопии почечной ткани.


  1. Desnick R., Ioannou Y., Eng C. Аlpha-Galactosidase A deficiency: Fabry disease. In: Scriver C.R. B.A., Sly W.S., Valle D. ed. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001: 3733-3774.
  2. Фомин В.В., Пулин А.А., Аксенова О.А. и др. Тяжелое поражение подоцитов, выявленное при электронной микроскопии почечного биоптата, у пациента с болезнью Фабри без выраженных изменений мочи и почечной недостаточности. Клинич нефрология 2012; 1: 55-58.
  3. Ortiz A., Cianciaruso B., Cizmarik M. et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 2010; 25: 769-775.
  4. Schiffmann R., Warnock D.G., Banikazemi M. et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24: 2102-2111.
  5. Branton M.H., Schiffmann R., Sabnis S.G. et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-138.
  6. West M., Nicholls K., Mehta A. et al. Agalsidase-alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009; 20: 1132-1139.
  7. Schiffmann R., Warnock D.G., Banikazemi M. et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24: 2102-2111.
  8. Jefferson J.A., Nelson P.J., Najafian B., Shankland S.J. Podocyte disorders: Core Curriculum 2011. Am. J Kidney Dis 2011; 58 (4): 666-677.
  9. Fogo A.B., Bostad L., Svarstad E. et al.; all members of the International Study Group of Fabry Nephropathy (ISGFN). Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010; 25 (7): 2168-2177.
  10. Najafian B., Mauer M., Hopkin R.J., Svarstad E. Renal complications of Fabry disease in children. Pediatr Nephrol 2013; 28 (5): 679-685.
  11. Eng C.M., Germain D.P., Banikazemi M. et al. Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genetics in Medicine 2006; 8 (9): 539-548.
  12. Mehta A., Ricci R., Widmer U. et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236-242.
  13. Whybra C., Miebach E., Mengel E. et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase-alfa in 36 women with Fabry disease. Genet Med 2009; 11: 441-449.
  14. Pisani A., Visciano B., Roux G.D. et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Mol Genet Metab 2012; 107 (3): 267-275.
  15. Tahir H., Jackson L.L., Warnock D.G. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007; 18: 2609-2617.
  16. Levey A.S. Clinical practice. Nondiabetic kidney disease. N Engl J Med 2002; 347: 1505-1511.
  17. Mehta A., West M.L., Pintos-Morell G. et al. Therapeutic goals in the treatment of Fabry disease. Genetics in Medicine 2010; 12 (11): 713-720.
  18. Maixnerová D., Tesa V., Ry Avá R. et al. The coincidence of IgA nephropathy and Fabry disease. BMC Nephrology 2013; 14 (1): 6.
  19. Kakita T., Nagatoya K., Mori T. et al. Coincidental finding of Fabry's disease in a patient with IgA nephropathy. Nephol Dial Transplant 2010; 3: 443-446.
  20. Shimohata H., Yoh K., Takada K. et al. Hemizygous Fabry disease associated with IgA nephropathy: a case report. J Nephrol 2009; 22 (5): 682-684.
  21. Zarate Y.A, Patterson L., Yin H. et al. A case of minimal change disease in a Fabry patient. Pediatr Nephrol 2009; 25 (3): 553-556.
  22. Singh H.K., Nickeleit V., Kriegsmann J. et al. Coexistence of Fabry's disease and necrotizing and crescentic glomerulonephritis. Clin Nephrol 2001; 55 (1): 73-79.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies